PROSTAGLANDIN J2

PROSTAGLANDIN J2 Property

Boiling point:

521.7±50.0 °C(Predicted)

Density 

1.103±0.06 g/cm3(Predicted)

storage temp. 

−20°C

solubility 

DMF: >100 mg/ml (from PGD2); DMSO: >50 mg/ml (from PGD2); Ethanol: >75 mg/ml (from PGD2); PBS pH 7.2: >2.7 mg/ml (from 15-deoxy-.DEL

pka

4.75±0.10(Predicted)

form 

Liquid

color 

Colorless to light yellow

Safety

Hazard Codes 

Xn,Xi,F

Risk Statements 

20/21/22-36/37/38-67-66-36-11

Safety Statements 

26-36-33-29-16

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H225Highly Flammable liquid and vapour

H319Causes serious eye irritation

H336May cause drowsiness or dizziness

Precautionary statements

P210Keep away from heat/sparks/open flames/hot surfaces. — No smoking.

P240Ground/bond container and receiving equipment.

P241Use explosion-proof electrical/ventilating/lighting/…/equipment.

P242Use only non-sparking tools.

P243Take precautionary measures against static discharge.

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P271Use only outdoors or in a well-ventilated area.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P303+P361+P353IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P312Call a POISON CENTER or doctor/physician if you feel unwell.

P337+P313IF eye irritation persists: Get medical advice/attention.

P370+P378In case of fire: Use … for extinction.

P403+P233Store in a well-ventilated place. Keep container tightly closed.

P403+P235Store in a well-ventilated place. Keep cool.

P405Store locked up.

P501Dispose of contents/container to..…

PROSTAGLANDIN J2 Chemical Properties,Usage,Production

Description

Prostaglandin J₂ (PGJ₂) is formed from PGD₂ by the elimination of the C-9 hydroxyl group, a process which is accelerated by the presence of albumin. PGJ₂ inhibits platelet aggregation with an IC₅₀ of about 5-10 nM. PGJ₂ has antimitotic and antiproliferative effects on a variety of cultured normal cells and tumor cell lines. However, this activity has been attributed to further metabolites of PGJ₂ and not the parent compound itself.

Uses

PGJ2 (Prostaglandin J2) is a Prostaglandin D2 metabolite that has shown potent anti-neoplastic and antiviral activity.

Definition

ChEBI: A member of the class of prostaglandins J that consists of prosta-5,9,13-trien-1-oic acid substituted by an oxo group at position 11 and a hydroxy group at position 15 (the 5Z,13E,15S stereoisomer).

in vivo

IC 50

hDP: 0.9 nM (Ki); hCRTH2: 6.6 nM (Ki); hEP1: 15.678 μM (Ki); hEP2: 989 nM (Ki); hEP3: 319 nM (Ki); hEP4: 1065 nM (Ki); hFP: 553 nM (Ki); hIP: >25 μM (Ki); hTP: 6426 nM (Ki); Human Endogenous Metabolite

References

[1] D. HAMISH WRIGHT. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist[J]. British Journal of Pharmacology, 2009, 123 7: 1317-1324. DOI: 10.1038/sj.bjp.0701708
[2] NICOLE SAWYER. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2[J]. British Journal of Pharmacology, 2009, 137 8: 1163-1172. DOI: 10.1038/sj.bjp.0704973
[3] TENEKA JEAN-LOUIS  Maria E F P  Patricia Rockwell. Prostaglandin J2 promotes O-GlcNAcylation raising APP processing by α- and β-secretases: relevance to Alzheimer’s disease[J]. Neurobiology of Aging, 2018, 62: Pages 130-145. DOI: 10.1016/j.neurobiolaging.2017.10.009
[4] MARIA E. FIGUEIREDO-PEREIRA  John B  Chuhyon Corwin. Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration?[J]. Annals of the New York Academy of Sciences, 2016, 1363 1: 125-137. DOI: 10.1111/nyas.12987
[5] CHUHYON CORWIN. Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets.[J]. Journal of Neuroinflammation, 2018: 272. DOI: 10.1186/s12974-018-1305-3
[6] ABHITA MALAVIYA  Paul W S. Synergistic Antiproliferative Effects of Combined γ -Tocotrienol and PPAR γ Antagonist Treatment Are Mediated through PPAR γ -Independent Mechanisms in Breast Cancer Cells.[J]. PPAR Research, 2014: 439146. DOI: 10.1155/2014/439146